A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Inclusion Criteria

• •Histologically confirmed Grade 1, 2, or 3a FL or nodal MZL, splenic MZL, or extra nodal MZL
• •Willingness to avoid pregnancy or fathering children
• •In the opinion of the investigator, be able and willing to receive adequate mandatory prophylaxis and/or therapy for thromboembolic events (eg, aspirin 70-325 mg daily or low-molecular-weight heparin)
• •Previously treated with at least 1 prior systemic anti-CD20 immunotherapy or chemo-immunotherapy
• •Documented relapsed, refractory, or PD after treatment with systemic therapy
• •ECOG performance status of 0 to 2